Vistagen Therapeutics, Inc.: Form 10-Q for the period ended Dec 31, 2025
Filed with the SEC on Feb 12, 2026 and accepted by EDGAR at Feb 12, 2026, 16:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-10-01 to 2025-12-31 | $303.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2025-04-01 to 2025-12-31 | $804.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 3 months2025-10-01 to 2025-12-31 | $14.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-04-01 to 2025-12-31 | $41.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-10-01 to 2025-12-31 | −$19.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-04-01 to 2025-12-31 | −$55.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-10-01 to 2025-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-04-01 to 2025-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-10-01 to 2025-12-31 | −$18.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-04-01 to 2025-12-31 | −$53.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-10-01 to 2025-12-31 | −$0.45 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-04-01 to 2025-12-31 | −$1.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-10-01 to 2025-12-31 | −$0.45 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-04-01 to 2025-12-31 | −$1.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-10-01 to 2025-12-31 | 42,234,405 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-04-01 to 2025-12-31 | 36,655,195 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-04-01 to 2025-12-31 | −$50.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-12-31 | $47.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $63.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $65.1m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $13.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $14.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $50.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-26-007718. Last ingested by Listed: Oct 30, 2026, 17:32 ET. Listed shows no prices and gives no investment advice.